Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.

Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR.

Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.

2.

In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.

Brock EJ, Ji K, Shah S, Mattingly RR, Sloane BF.

J Mammary Gland Biol Neoplasia. 2018 Jul 28. doi: 10.1007/s10911-018-9405-3. [Epub ahead of print] Review.

PMID:
30056557
3.

Ras and Rap1: A tale of two GTPases.

Shah S, Brock EJ, Ji K, Mattingly RR.

Semin Cancer Biol. 2018 Apr 3. pii: S1044-579X(18)30003-8. doi: 10.1016/j.semcancer.2018.03.005. [Epub ahead of print] Review.

PMID:
29621614
4.

Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.

Kraniak JM, Chalasani A, Wallace MR, Mattingly RR.

Exp Neurol. 2018 Jan;299(Pt B):289-298. doi: 10.1016/j.expneurol.2017.10.012. Epub 2017 Oct 19.

PMID:
29055717
5.

Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.

Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF.

Breast Cancer Res. 2017 May 15;19(1):56. doi: 10.1186/s13058-017-0847-0.

6.

Phosphorylation of rat kidney Na-K pump at Ser938 is required for rapid angiotensin II-dependent stimulation of activity and trafficking in proximal tubule cells.

Massey KJ, Li Q, Rossi NF, Keezer SM, Mattingly RR, Yingst DR.

Am J Physiol Cell Physiol. 2016 Feb 1;310(3):C227-32. doi: 10.1152/ajpcell.00113.2015. Epub 2015 Nov 18.

7.

How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Brock EJ, Ji K, Reiners JJ, Mattingly RR.

Mini Rev Med Chem. 2016;16(5):358-69. Review.

8.

Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.

Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF.

BMC Cancer. 2015 Aug 13;15:584. doi: 10.1186/s12885-015-1576-3.

9.

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.

Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL.

Breast Cancer Res Treat. 2014 Sep;147(2):283-93. doi: 10.1007/s10549-014-3102-8. Epub 2014 Aug 17.

10.

Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins.

Mattingly RR.

ISRN Oncol. 2013 Oct 31;2013:536529. doi: 10.1155/2013/536529. eCollection 2013. Review.

11.

Acid-mediated tumor proteolysis: contribution of cysteine cathepsins.

Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, Moin K, Blum G, Mattingly RR, Gillies RJ, Sloane BF.

Neoplasia. 2013 Oct;15(10):1125-37.

12.

Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R.

J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.

13.

Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Kaur H, Mao S, Shah S, Gorski DH, Krawetz SA, Sloane BF, Mattingly RR.

Expert Rev Mol Diagn. 2013 Mar;13(2):151-65. doi: 10.1586/erm.13.4. Review.

14.

Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A.

Hammer A, Rider L, Oladimeji P, Cook L, Li Q, Mattingly RR, Diakonova M.

Mol Endocrinol. 2013 Mar;27(3):455-65. doi: 10.1210/me.2012-1291. Epub 2013 Jan 22.

15.

RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.

Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR.

PLoS One. 2012;7(12):e50249. doi: 10.1371/journal.pone.0050249. Epub 2012 Dec 6.

16.

MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression.

Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF.

J Vis Exp. 2012 Feb 17;(60). pii: 3661. doi: 10.3791/3661.

17.

3D/4D functional imaging of tumor-associated proteolysis: impact of microenvironment.

Moin K, Sameni M, Victor BC, Rothberg JM, Mattingly RR, Sloane BF.

Methods Enzymol. 2012;506:175-94. doi: 10.1016/B978-0-12-391856-7.00034-2.

18.

Angiotensin II-dependent phosphorylation at Ser11/Ser18 and Ser938 shifts the E2 conformations of rat kidney Na+/K+-ATPase.

Massey KJ, Li Q, Rossi NF, Mattingly RR, Yingst DR.

Biochem J. 2012 Apr 1;443(1):249-58. doi: 10.1042/BJ20111398.

19.

Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin.

Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ Jr, Mattingly RR.

J Pharmacol Exp Ther. 2011 Apr;337(1):65-74. doi: 10.1124/jpet.110.174573. Epub 2011 Jan 12.

20.

The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.

Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA.

Mol Cell Biochem. 2010 Nov;344(1-2):267-76. doi: 10.1007/s11010-010-0551-1. Epub 2010 Aug 1.

21.

A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.

Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F, Borch RF, Reiners JJ Jr, Gibbs RA, Mattingly RR.

J Pharmacol Exp Ther. 2010 Apr;333(1):23-33. doi: 10.1124/jpet.109.160192. Epub 2010 Jan 19.

22.

Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.

Li Q, Chow AB, Mattingly RR.

J Pharmacol Exp Ther. 2010 Mar;332(3):821-8. doi: 10.1124/jpet.109.160390. Epub 2009 Dec 1.

23.

Working together: Farnesyl transferase inhibitors and statins block protein prenylation.

Wojtkowiak JW, Gibbs RA, Mattingly RR.

Mol Cell Pharmacol. 2009 Jan 1;1(1):1-6.

25.

Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN.

Cancer Biol Ther. 2008 Dec;7(12):1938-46. Epub 2008 Dec 7.

27.

Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.

Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ Jr, Borch RF, Mattingly RR.

J Pharmacol Exp Ther. 2008 Jul;326(1):1-11. doi: 10.1124/jpet.107.135830. Epub 2008 Mar 26.

28.

Angiotensin II stimulates elution of Na-K-ATPase from a digoxin-affinity column by increasing the kinetic response to ligands that trigger the decay of E2-P.

Yingst DR, Doci TM, Massey KJ, Rossi NF, Rucker E, Mattingly RR.

Am J Physiol Renal Physiol. 2008 Apr;294(4):F990-F1000. doi: 10.1152/ajprenal.00492.2007. Epub 2008 Feb 13.

29.

Low and nontoxic inorganic mercury burdens attenuate BCR-mediated signal transduction.

McCabe MJ Jr, Laiosa MD, Li L, Menard SL, Mattingly RR, Rosenspire AJ.

Toxicol Sci. 2007 Oct;99(2):512-21. Epub 2007 Jul 26.

PMID:
17656488
30.

Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors.

Clark MK, Scott SA, Wojtkowiak J, Chirco R, Mathieu P, Reiners JJ Jr, Mattingly RR, Borch RF, Gibbs RA.

J Med Chem. 2007 Jul 12;50(14):3274-82. Epub 2007 Jun 8.

PMID:
17555307
31.

Epac- and Rap- independent ERK1/2 phosphorylation induced by Gs-coupled receptor stimulation in HEK293 cells.

Norum JH, Dawood H, Mattingly RR, Sandnes D, Levy FO.

FEBS Lett. 2007 Jan 9;581(1):15-20. Epub 2006 Dec 4.

32.

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ Jr, Mattingly RR.

Biochem Pharmacol. 2006 Nov 30;72(11):1485-92. Epub 2006 Apr 28. Review.

PMID:
16797490
33.

The Ras-GRF1 exchange factor coordinates activation of H-Ras and Rac1 to control neuronal morphology.

Yang H, Mattingly RR.

Mol Biol Cell. 2006 May;17(5):2177-89. Epub 2006 Feb 15.

34.

Inorganic mercury inhibits the activation of LAT in T-cell receptor-mediated signal transduction.

Ziemba SE, Mattingly RR, McCabe MJ Jr, Rosenspire AJ.

Toxicol Sci. 2006 Jan;89(1):145-53. Epub 2005 Oct 26.

PMID:
16251484
35.

The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.

Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, Benjamins JA, Tainsky MA, Reiners JJ Jr.

J Pharmacol Exp Ther. 2006 Jan;316(1):456-65. Epub 2005 Oct 20.

PMID:
16239399
36.

Active p21-activated kinase 1 rescues MCF10A breast epithelial cells from undergoing anoikis.

Menard RE, Jovanovski AP, Mattingly RR.

Neoplasia. 2005 Jul;7(7):638-45.

38.

Angiotensin II directly stimulates activity and alters the phosphorylation of Na-K-ATPase in rat proximal tubule with a rapid time course.

Yingst DR, Massey KJ, Rossi NF, Mohanty MJ, Mattingly RR.

Am J Physiol Renal Physiol. 2004 Oct;287(4):F713-21. Epub 2004 May 25.

39.

TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines.

Chopra DP, Menard RE, Januszewski J, Mattingly RR.

Cancer Lett. 2004 Jan 20;203(2):145-54.

PMID:
14732222
41.
42.
43.

Phosphorylation of the Ras-GRF1 exchange factor at Ser916/898 reveals activation of Ras signaling in the cerebral cortex.

Yang H, Cooley D, Legakis JE, Ge Q, Andrade R, Mattingly RR.

J Biol Chem. 2003 Apr 11;278(15):13278-85. Epub 2003 Jan 21.

44.
45.

Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.

Keshamouni VG, Mattingly RR, Reddy KB.

J Biol Chem. 2002 Jun 21;277(25):22558-65. Epub 2002 Apr 17.

46.

High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis.

Beqaj S, Jakkaraju S, Mattingly RR, Pan D, Schuger L.

J Cell Biol. 2002 Mar 4;156(5):893-903. Epub 2002 Mar 4.

47.

Low concentrations of inorganic mercury inhibit Ras activation during T cell receptor-mediated signal transduction.

Mattingly RR, Felczak A, Chen CC, McCabe MJ Jr, Rosenspire AJ.

Toxicol Appl Pharmacol. 2001 Nov 1;176(3):162-8.

PMID:
11714248
48.
50.

Activation of the Ras-GRF/CDC25Mm exchange factor by lysophosphatidic acid.

Mattingly RR, Saini V, Macara IG.

Cell Signal. 1999 Aug;11(8):603-10.

PMID:
10433521

Supplemental Content

Loading ...
Support Center